Children's Oncology Group's 2013 blueprint for research: Renal tumors |
| |
| Authors: | Jeffrey S Dome MD PhD Conrad V Fernandez MD Elizabeth A Mullen MD John A Kalapurakal MD James I Geller MD Vicki Huff PhD Eric J Gratias MD David B Dix MD Peter F Ehrlich MD Geetika Khanna MD Marcio H Malogolowkin MD James R Anderson PhD Arlene Naranjo PhD Elizabeth J Perlman MD |
| |
| Institution: | 1. Division of Oncology, Center for Cancer and Blood Disorders, Children's National Medical Center, Washington, District of Columbia;2. Division of Pediatric Hematology/Oncology, IWK Health Centre, Halifax, Nova Scotia, Canada;3. Pediatric Hematology/Oncology, Dana Farber Cancer Institute, Boston, Massachusetts;4. Department of Radiation Oncology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois;5. Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio;6. Department of Genetics, MD Anderson Cancer Center, Houston, Texas;7. Division of Hematology/Oncology, Children's Hospital at Erlanger, University of Tennessee College of Medicine, Chattanooga, Tennessee;8. Pediatric Hematology/Oncology, British Columbia Children's Hospital, Vancouver, British Columbia, Canada;9. Department of Pediatric Surgery, University of Michigan, CS Mott Children's Hospital, Ann Arbor, Michigan;10. Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri;11. Division of Hematology/Oncology/Bone Marrow Transplant, Children's Hospital of Wisconsin;12. University of Nebraska Medical Center, Omaha, Nebraska;13. Department of Biostatistics, Colleges of Medicine and Public Health & Health Professions, University of Florida, Gainesville, Florida;14. Department of Pathology, Northwestern University's Feinberg School of Medicine and the Robert H. Lurie Cancer Center, Chicago, Illinois |
| |
| Abstract: | Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5‐year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high‐risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented. Pediatr Blood Cancer 2013; 60: 994–1000. © 2012 Wiley Periodicals, Inc. |
| |
| Keywords: | clear cell sarcoma malignant rhabdoid tumor renal cell carcinoma Wilms tumor |
|
|
